BS_VAAHBH60
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 46.08
- os_event
- false
- age_years
- 6.397
- sex
- F
- race
- White
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.272709751
- umap2_2d
- 1.096027627
- umap1_3d
- 0.457531573
- umap2_3d
- 3.338289519
- umap3_3d
- -3.252066756
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.410
- MYC_TARGETS_V2+0.170
- SPERMATOGENESIS+0.120
- WNT_BETA_CATENIN_SIGNALING+0.110
- MITOTIC_SPINDLE+0.100
- KRAS_SIGNALING_DN+0.040
- APICAL_SURFACE+0.030
- DNA_REPAIR-0.050
- NOTCH_SIGNALING-0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.470
- OXIDATIVE_PHOSPHORYLATION-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- ALLOGRAFT_REJECTION-0.420
- CHOLESTEROL_HOMEOSTASIS-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
- ADIPOGENESIS-0.400
- MTORC1_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VAAHBH60 | Supratentorial Ependymoma | — | 0.958 |
| 2 | BS_4E1G7E3G | ATRT | — | 0.949 |
| 3 | BS_4W68NV3M | medulloblastoma | — | 0.941 |
| 4 | SAMN03290905 | — | — | 0.939 |
| 5 | C3N-03886 | — | cohortMD1 | 0.936 |
| 6 | BS_S1M423AB | Embryonal tumors | — | 0.935 |
| 7 | BS_44A3ES23 | medulloblastoma | — | 0.928 |
| 8 | BS_77317DY4 | medulloblastoma | — | 0.920 |
| 9 | BS_9FHSNVS0 | ATRT | — | 0.919 |
| 10 | c01b5135.b754.4c57.a81d.68a951803fab | — | cohortMD1 | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |